GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Distigmin (ATC-Code nach WHO: N07AA03)

Health · Germany government procurement

Closed October 31, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) by way of an open-house model for the active ingredient distigmine (ATC code according to WHO: N07AA03)

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedAugust 16, 2024
Procurement stageActive solicitation
ClosedOctober 31, 2026
StatusClosed — no longer accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Browse Similar Open Opportunities in Germany

Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Trastuzumab, ATC L01FD01 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brimonidin + Timolol, ATC S01ED69 für die Zeit 01.02.2026 - 31.01.2028 (zzgl. Verlängerungsoption 1x12 Mon.)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risperidon in der Darreichungsform Pulver und Lösungsmittel zur Herstellung einer Injektionslösung, ATC N05AX08
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-24 - Vericiguat
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Vareniclin (ATC: N07BA03)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Adapalen + Benzoylperoxid, ATC D10AD23 für die Zeit 01.02.2026 - 31.01.2028 (zzgl. V.-Option 1x12 Monate)
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Formoterol und Beclometason dipropionat, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/4,91µg, ATC R03AK08
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Peginterferon beta-1a, ATC L03AB13 für die Zeit 01.05.2025 - 30.04.2027

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.